Pascale Witz

Pascale Witz is the current director at PerkinElmer. Pascale has also previously served on the board of directors for TESARO, Inc., Horizon, Regulus Therapeutics, PWH Advisors, and Global Alzheimer's Platform Foundation. In addition, they have worked with Fresenius Medical Care and Groupe SAVENCIA.

Pascale Witz has a long history of working in the field of molecular biology. Pascale has isolated and cloned a 5HT2 serotonin receptor in the drosophila brain. In addition, they have also worked on developing treatments for Alzheimer's disease.

Pascale Witz has a Master of Business Administration (M.B.A.) from INSEAD with a focus in Economics & Marketing, as well as a Master's Degree from INSA Lyon - Institut National des Sciences Appliquées de Lyon in Molecular Biology / Biochemistry / Life Sciences. Pascale also has a certification from INSEAD in "Strategy in the Age of Digital Disruption."